Summary
Bifeprunox, a partial dopamine agonist, is being developed as a possible treatment for schizophrenia. The results of a 6-month randomized, double-blind, placebo-controlled study of 497 patients with schizophrenia.
- Obesity Clinical Trials
- Schizophrenia
- © 2007 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.